{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959004",
  "id": "02959004",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250617",
  "time": "0829",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt6st9534k2w.pdf",
  "summary": "### Summary of ASX Announcement:  \n**Type: Clinical Trial Update (Non-Capital Markets Event)**  \n\n- **Key Clinical Findings:**  \n  - CHM CDH17 CAR-T cells demonstrated **persistence up to 6 months** post-infusion in 2 subjects (Dose Level 1).  \n  - Translational data confirms **target (CDH17) presence** in all 4 treated subjects' tumors.  \n  - **Dose Level 2** enrollment ongoing in Phase 1/2 trial (NCT06055439) for advanced GI cancers.  \n\n- **Material Implications:**  \n  - Positive early **proof-of-concept** for CAR-T durability, potentially **de-risking further development**.  \n  - No financial or capital structure impacts disclosed.  \n\n**No material trading/capital markets information identified** (e.g., no raising, halt, or liquidity changes).  \n\n*(Note: Omits background, CEO quotes, and non-material pipeline details.)*",
  "usage": {
    "prompt_tokens": 1278,
    "completion_tokens": 204,
    "total_tokens": 1482,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T22:48:42.865114"
}